Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens(PERFORMANCE) | terminated | Phase 1 | 27 | Eric Thompson, M.D.OTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT03332589 | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | terminated | Phase 1 | 4 | Spirita Oncology, LLCINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02163356 | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma(SPOC2013-001) | terminated | Phase 1 | 4 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02687386 | A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR(ECREST) | terminated | Phase 1 | 9 | Dr David ZieglerOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | terminated | Phase 1 | 4 | Klinikum StuttgartOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT03422094 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | terminated | Phase 1 | 3 | Washington University School of MedicineOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT00633958 | A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors(FLT) | terminated | Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01058850 | Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas | terminated | Phase 1 | 3 | Paul Graham FisherOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01110876 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02046187 | Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | terminated | Phase 1 / Phase 2 | 14 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02433392 | Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme. | terminated | Phase 1 | 9 | Boston Scientific CorporationINDUSTRY | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02481960 | Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma(IDEB-glioma) | terminated | Phase 1 / Phase 2 | 5 | Boston Scientific CorporationINDUSTRY | 2 | Apr 21, 2021 | clinicaltrials |
| NCT03050450 | Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors | terminated | Phase 1 | 8 | Johns Hopkins All Children's HospitalOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM(INTERCEPT) | terminated | Phase 1 | 2 | Gary Archer Ph.D.OTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02116959 | Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma | terminated | Phase 1 | 6 | University of California, San FranciscoOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02855086 | Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery | terminated | Phase 1 / Phase 2 | 3 | Eben RosenthalOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT04327011 | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | terminated | Phase 1 | 65 | Tocagen Inc.INDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01400672 | Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | terminated | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT03573986 | Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment | terminated | Phase 1 | 2 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02764151 | First in Patient Study for PF-06840003 in Malignant Gliomas | terminated | Phase 1 | 17 | PfizerINDUSTRY | 1 | Jan 27, 2020 | clinicaltrials |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00108056 | Enzastaurin to Treat Recurrent Brain Tumor | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2019 | clinicaltrials |
| NCT01747876 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | terminated | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 5 | Nov 22, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01065805 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma | terminated | Phase 1 / Phase 2 | 94 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT03246113 | Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | terminated | Phase 1 | 1 | New York State Psychiatric InstituteOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02629549 | Intraoperative Imaging of Pituitary Adenomas by OTL | terminated | Phase 1 | 33 | University of PennsylvaniaOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT04002804 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme(Dendr2) | terminated | Phase 1 | 26 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 0 | Jul 1, 2019 | clinicaltrials |
| NCT01582152 | Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2019 | clinicaltrials |
| NCT01601184 | Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway | terminated | Phase 1 / Phase 2 | 24 | Centre Leon BerardOTHER | 4 | May 21, 2019 | clinicaltrials |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | terminated | Phase 1 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT00801931 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | terminated | Phase 1 / Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00895960 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | terminated | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT00038389 | Study of Vioxx and Radiation Therapy for Brainstem Glioma | terminated | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT02337309 | SF1126 for Patients With Relapsed or Refractory Neuroblastoma | terminated | Phase 1 | 4 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT02176720 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | terminated | Phase 1 | 31 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma | terminated | Phase 1 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00880061 | An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma | terminated | Phase 1 | 7 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02305056 | Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)(CARBONOMIC) | terminated | Phase 1 | 6 | University Hospital, GrenobleOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | terminated | Phase 1 / Phase 2 | 1 | University of LouisvilleOTHER | 1 | May 4, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jun 9, 2022source: clinicaltrials